Home Healthcare Software As A Medical Device (SaMD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Home Healthcare Software As A Medical Device (SaMD) Market Trends and Insights

Expansion of Home-Based Chronic Disease Management

Cardiovascular disease, diabetes, and respiratory conditions continued to increase pressure on care teams beyond clinic-based care. The Home Healthcare SaMD Market supports remote measurement, clinical risk assessment, and care plan adjustments for patients at home. In June 2026, Dexcom reported that its CONNECT randomized controlled study showed a statistically significant HbA1c reduction among people with Type 2 diabetes who were not using insulin and used G7-based monitoring compared with routine care. This evidence gave payers a clearer basis for evaluating home-based monitoring in chronic disease programs.

Workforce Shortages Increasing Demand for Clinical Automation

Staffing pressure increased the value of scheduling, documentation, and care coordination tools in home care. In January 2026, Axxess reported that more than 60% of care-at-home organizations identified recruitment and retention as their main challenge entering 2026. The Home Healthcare SaMD Market is responding with tools that reduce repetitive administrative work and improve clinician schedule management. In March 2026, Homecare Homebase introduced Curate Scribe, which is designed to reduce start-of-care documentation by 35-45 minutes per admission.

Growth of Remote Patient Monitoring and Virtual Care

Remote patient monitoring expanded as organizations built services connecting hospital discharge, home monitoring, and clinical follow-up. The Home Healthcare SaMD Market includes tools that integrate connected device data into clinical workflows. In June 2026, Dexcom was selected as the first participant in the FDA TEMPO Digital Health Devices Pilot Program for an artificial intelligence-enabled glucose program combining G7 and Stelo data with nutrition, activity, sleep, and stress information. These programs increased the need for reliable links between devices, patient records, and clinical teams.

Reimbursement and Value-Based Care Incentives

Value-based care contracts increased demand for tools that demonstrate the link between home monitoring and patient outcomes. The Home Healthcare SaMD Market becomes more attractive to providers when software supports reporting for payer performance measures. Teladoc Health stated in its 2025 annual report that it is deploying artificial intelligence-enabled stratification capabilities in 2026 to help care teams personalize chronic condition management and reduce hospitalizations among higher-risk members. The FDA’s August 2025 final guidance on Predetermined Change Control Plans also provided a path for accepted planned modifications to AI-enabled device software functions.

Cybersecurity, Privacy, and Healthcare Data-Protection Requirements

Cybersecurity has become a key purchasing consideration for connected home care systems. In July 2026, AdaptHealth disclosed that a threat actor gained unauthorized access to certain cloud-based patient management systems, document storage platforms, and external electronic health record portals through a social-engineering incident. The incident involved protected health information and insurance billing credentials, highlighting the sensitivity of home care systems. The Home Healthcare SaMD Market faces longer vendor review cycles as agencies assess cloud controls, third-party access, native access controls, anomaly detection, independent security assurance, HIPAA Security Rule compliance, clinical liability, and data quality controls.

Home-Environment Data Quality and Algorithm Generalizability Risk

Home-based data can vary as patients use different devices, follow different routines, and receive care in diverse settings. An algorithm that performs well with one monitoring device may not deliver the same performance after a patient changes equipment, especially in regions with uneven device access and connectivity. Data quality checks, device-specific validation, and continuous model performance monitoring can reduce this risk, but they require time and technical resources that may slow implementation for smaller providers. The issue remains especially relevant when software supports clinical recommendations.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Clinical Decision Support Leads While Remote Monitoring Grows Quickly

Clinical Decision Support Software held 34.35% of Home Healthcare SaMD Market share in 2025. It supported chronic disease programs by embedding risk assessment, protocol guidance, and alerts within the home health electronic record workflow, reducing the need for clinicians to switch between applications during care delivery. WellSky launched its Point of Care app in May 2026, combining AI-supported workflows, clinical intelligence, and patient records on a clinician’s mobile device. The company stated that its Scribe feature could reduce charting time by up to 50% across more than 400 home health agencies.

Remote Patient Monitoring Software is forecast to expand at a 15.93% CAGR through 2031. Growth reflects the broader installed base of home monitoring hardware and the value of continuous patient data after hospital or clinic discharge. Digital therapeutics also contribute to the product mix, with Omada Health reporting more than 2 million members and more than 2,000 employer and health-plan clients in its 2025 results. Suppliers are linking documentation, communication, and patient monitoring within one workflow to reduce duplicate entry and support timely clinical action.

By SaMD Risk Classification: Moderate-Risk Systems Lead While Low-Risk Tools Expand

Moderate-Risk SaMD accounted for 55.45% of the Home Healthcare SaMD Market in 2025. This classification includes many clinically used cardiovascular and diabetes management tools that require 510(k) clearance but not the more demanding premarket approval route. These systems often combine diagnostic support with care coordination, and manufacturers must validate performance because malfunctions could affect patient safety. Device makers with established evidence and regulatory documentation can gain an advantage in this segment.

Low-Risk SaMD is forecast to grow at a 17.67% CAGR through 2031. Growth reflects opportunities in wellness coaching, sleep analysis, and lifestyle data applications with lower direct clinical risk. The FDA issued updated guidance for Clinical Decision Support Software in January 2026, clarifying criteria that help distinguish certain non-device clinical decision support functions. High-Risk SaMD remains smaller but strategically important for autonomous diagnostic tools and closed-loop insulin delivery, with Medtronic announcing FDA clearance of its MiniMed Flex system in 2025, including the SmartGuard algorithm and Meal Detection technology.

By Deployment: Cloud-Based Platforms Lead While Hybrid Systems Address Security Needs

Cloud-Based SaMD held 62.33% of the Home Healthcare SaMD Market in 2025. Cloud delivery supports expansion across dispersed care teams, consolidates reporting data, and enables regular updates and integration with care-management services. AlayaCare introduced autonomous agents in March 2026 and stated that these capabilities could reduce manual workload by up to 80%. It also established an API integration with Inovalon ScriptMed in January 2026 to connect nursing management and pharmacy workflows.

Hybrid Deployment is forecast to grow at a 16.35% CAGR through 2031. It allows health systems to keep selected patient identifiers within local infrastructure while using cloud resources for defined analytical workloads. This model is relevant for organizations with strict data protection policies or sensitive information storage requirements. On-Premise SaMD remains relevant for hospital-affiliated programs and jurisdictions with data localization requirements.

By Application: Cardiovascular Care Leads While Neurological Monitoring Gains Pace

Cardiovascular Disease Management accounted for 28.88% of the Home Healthcare SaMD Market in 2025. The application supports hypertension, arrhythmia, and heart failure management, where early identification of worsening symptoms can help care teams respond. Team Select Home Care expanded CareSightAI to cardiac patients in 2026 after deploying the platform nationally for respiratory patients in December 2025. Dexcom received FDA clearance in May 2026 for the Stelo Glucose Biosensor System, including a Glucose Response Score for logged meals and AI-generated insight summaries.

Neurological Disorder Management is forecast to grow at a 17.78% CAGR through 2031. Home-based care remains relevant for people with Alzheimer’s disease, Parkinson’s disease, and post-stroke rehabilitation needs that require regular observation. Wearable electroencephalogram devices, gait assessment platforms, and speech-pattern tools are emerging for this purpose. ResMed launched AirConnect Dx for United Kingdom National Health Service sleep services in May 2026, combining referral management, home sleep testing, reporting, logistics, and patient support.

By End User: Hospices Lead Adoption While Home Health Agencies Grow Fastest

Hospices and Palliative Care Providers accounted for 47.89% of the Home Healthcare SaMD Market in 2025. These settings require coordinated symptom monitoring, medication management, family communication, and timely documentation. Their quality reporting responsibilities increase the value of tools that support complete care records. Axxess stated in July 2026 that its Axxess Intelligence ecosystem served more than 10,000 organizations globally and provided business intelligence tools for care-at-home providers.

Home Health Agencies are forecast to grow at a 16.45% CAGR through 2031. Value-based purchasing and higher referral volumes are increasing the need for systems that improve efficiency without reducing care quality. HHAeXchange presented a redesigned caregiver mobile application, a Visit Maintenance dashboard, and embedded payroll tools at Care Forward 2026. Sensi.AI stated in July 2026 that its Care Intelligence platform had been extended through a preferred partnership with SYNERGY HomeCare across more than 250 franchise locations.

Geography Analysis

North America held 39.66% of the Home Healthcare SaMD Market share in 2025. The region had a large base of home health agencies, established reimbursement structures, and mature clinical technology use. The United States remained the key demand center, as home-based care providers needed tools for monitoring, documentation, and care coordination. Canada and Mexico remained secondary markets as virtual care was incorporated into home and community care services.

Asia-Pacific is forecast to expand at a 15.56% CAGR through 2031. Rising chronic disease needs and national digital health programs are supporting demand for home monitoring and care-management systems. China, India, Japan, and South Korea each have different health financing and regulatory approaches. Suppliers entering the region need to account for national registration requirements as broader SaMD frameworks become more aligned.

Europe has a meaningful regional position, led by Germany, the United Kingdom, France, Italy, and Spain. Publicly funded systems create demand for tools that can expand service capacity without equivalent capital investment. The Middle East and Africa and South America remain smaller but developing areas of demand, supported by digital health infrastructure investments in Saudi Arabia and the United Arab Emirates and Brazil’s telehealth reimbursement framework. Regional growth will not follow a uniform path, making local partnerships, adaptable workflows, and country-specific implementation plans critical for long-term adoption.